Tenofovir DF in rescue regimens;Tenofovir DF en pautas de rescate

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 8, 2008, Pages 25-30

  de Quirós, Juan Carlos López Bernaldo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

K65R; Rescue therapy; Tenofovir

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TREATMENT FAILURE; EMERGENCY TREATMENT; GASTROINTESTINAL SYMPTOM; GENE INDUCTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PHARMACOGENETICS; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 74549181507     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13126269     Document Type: Article

References (26)

1. Panel de expertos de Gesida y PNS. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizado, Ene 2008) (accedido, May 2008). Disponible en: http://www.gesida.seimc.org/index.asp
2. Whitcomb J.M., Parkin N., Chappey C., Hellman N.S., and Petropoulos C.J. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 188 (2003) 992-1000
3. Shulman N., and Winters M. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr Drug Targets Infect Disord 3 (2003) 273-281
4. Wolf K., Walter H., Beerenwinkel N., Keulen W., Kaiser R., Hoffmann D., et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 47 (2003) 3478-3484
5. HIV Drug Resitance Database. Stanford University. Genotype-Phenotype Correlations (accedido, 25 May 2008). Disponible en: http://hivdb.stanford.edu/pages/genotype-phenotype.html
6. Winston A., Pozniak A., Mandalia S., Gazzard B., Pillay D., and Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 18 (2004) 949-951
7. Mendoza C., Jiménez-Nacher I., Garrido C., Barreiro P., Poveda E., Corral A., et al. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. Clin Infect Dis 46 (2008) 1782-1785
8. Winston A., Mandalia S., Pillay D., Gazzard B., and Pozniak A. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS 16 (2002) 2087-2089
9. Wirden M., Marcelin A.G., Simon A., Kirstetter M., Tubiana R., Valantin M.A., et al. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. J Med Virol 76 (2005) 297-301
10. Parikh U.M., Barnas D.C., Faruki H., and Mellors J.W. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 194 (2006) 651-660
11. Gallant J.E., Staszewski S., Pozniak A., DeJesus E., Suleiman H., Miller M., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. JAMA 292 (2004) 191-201
12. Miller M., Margot N., McColl D., Wring T., Coakley D., and Cheng A. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antivir Ther 8 (2003) 151
13. Von Wyl V., Yerly S., Boni J., Burgisser P., Klimkait T., Battegay M., et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases 46 (2008) 1299-1309
14. Kagan R., Ross L., Winters M., Merigan T., Heseltine P., and Lewinski M. Adefovirassociated HIV-1 RT mutation K70E in the age of tenofovir. Antiviral Ther 10 Suppl 1 (2005) S103
15. Ross L., Gerondelis P., Liao Q., Wine B., Lim M., Shaefer M., et al. Selection of the HIV-1 reverse transcriptase mutation, K70E in antiretroviral-naïve subjects treated with tenfovir/abacavir/lamivudine, therapy. Antiviral Ther 10 Suppl 1 (2005) S102
16. Kagan R.M., Lee T.S., Ross L., Lloyd R.M., Lewinski M.A., and Potts S.J. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Research 75 (2007) 210-218
17. Bennett M., Detorio M., Lennerstand J., Brun-Vezinet F., Descamps D., and Schinazi R.F. Characterization of the Q151M and V111I mutations of HIV-2 reverse transcriptase. XVI International HIV drug Resistance Workshop: Basic Principles & Clinical Implications. Barbados, Julio (2007) [abstract 109]
18. Winters M.A., and Merigan T.C. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother 49 (2005) 2575-2582
19. Rhee S.Y., Taylor J., Wadhera G., Ben-Hur A., Brutlag D.L., and Shafer R.W. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 103 (2006) 17355-17360
20. Svarovskaia E., Margot N., Bae A., Waters J., Goodman D., Zhong L., et al. Lowlevel K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J AIDS 46 (2007) 174-180
21. Schooley R.T., Ruane P., Myers R.A., Beall G., Lampiris H., Berger D., et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16 (2002) 1257-1263
22. Squires K., Pozniak A.L., Pierone G., Steinhart C.R., Berger D., Bellos N.C., et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. A randomized trial. Ann Intern Med 139 (2003) 313-320
23. Miller M.D., Margot N., Lu B., Zhong L., Chen S.S., Cheng A., et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189 (2004) 837-846
24. McColl D.J., Margot N.A., Wulfsoh M., Coakley D.F., Cheng A.K., and Miller M.D. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J AIDS 37 (2004) 1340-1345
25. Masquelier B., Tamalet C., Montes B., Descamps D., Peytavin G., Bocket L., et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 9 (2004) 315-323
26. Antinori A., Trotta M.P., Nasta P., Bini T., Bonora S., Castagna A., et al. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antivir Ther 11 (2006) 233-243